Bessemer Group
TEVA icon

Bessemer Group’s Teva Pharmaceuticals TEVA Stock Holding History

Bessemer Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189M Buy
5,581,600
+1,231,117
+28% +$41M 0.26% 96
2026
Q1 		$131M Buy
4,350,483
+70,058
+2% +$2.25M 0.21% 122
2025
Q4 		$134M Buy
4,280,425
+4,279,928
+861,153% +$105M 0.21% 119
2025
Q3 		$11K Buy
497
+146
+42% +$2.56K ﹤0.01% 1922
2025
Q2 		$5K Hold
351
– – ﹤0.01% 2045
2025
Q1 		$5K Buy
351
+84
+31% +$1.5K ﹤0.01% 2043
2024
Q4 		$6K Hold
267
– – ﹤0.01% 1970
2024
Q3 		$4K Buy
267
+87
+48% +$1.52K ﹤0.01% 2043
2024
Q2 		$3K Hold
180
– – ﹤0.01% 1899
2024
Q1 		$3K Buy
+180
New +$2.27K ﹤0.01% 1902
2023
Q1 		– Sell
-2,670
Closed -$26.4K – 2069
2022
Q4 		$24K Buy
2,670
+2,500
+1,471% +$21.8K ﹤0.01% 1279
2022
Q3 		$1K Hold
170
– – ﹤0.01% 1993
2022
Q2 		$1K Sell
170
-803
-83% -$7K ﹤0.01% 1839
2022
Q1 		$9K Sell
973
-1,906
-66% -$15.9K ﹤0.01% 1413
2021
Q4 		$23K Buy
2,879
+1,520
+112% +$13.7K ﹤0.01% 1249
2021
Q3 		$13K Buy
1,359
+137
+11% +$1.28K ﹤0.01% 1321
2021
Q2 		$12K Sell
1,222
-3,070
-72% -$32.5K ﹤0.01% 1320
2021
Q1 		$50K Buy
4,292
+838
+24% +$9.61K ﹤0.01% 1012
2020
Q4 		$33K Hold
3,454
– – ﹤0.01% 1081
2020
Q3 		$31K Hold
3,454
– – ﹤0.01% 993
2020
Q2 		$43K Buy
3,454
+580
+20% +$6.56K ﹤0.01% 1366
2020
Q1 		$26K Buy
2,874
+50
+2% +$512 ﹤0.01% 1325
2019
Q4 		$28K Sell
2,824
-50
-2% -$446 ﹤0.01% 1337
2019
Q3 		$20K Buy
2,874
+11
+0.4% +$84 ﹤0.01% 1405
2019
Q2 		$26K Hold
2,863
– – ﹤0.01% 1399
2019
Q1 		$45K Sell
2,863
-249
-8% -$4.39K ﹤0.01% 1294
2018
Q4 		$48K Buy
3,112
+141
+5% +$2.89K ﹤0.01% 1331
2018
Q3 		$64K Buy
2,971
+64
+2% +$1.49K ﹤0.01% 1224
2018
Q2 		$71K Buy
2,907
+2,703
+1,325% +$55.1K ﹤0.01% 1185
2018
Q1 		$4K Hold
204
– – ﹤0.01% 1567
2017
Q4 		$4K Sell
204
-412
-67% -$6.2K ﹤0.01% 1587
2017
Q3 		$11K Hold
616
– – ﹤0.01% 1590
2017
Q2 		$20K Sell
616
-247
-29% -$7.64K ﹤0.01% 1480
2017
Q1 		$28K Sell
863
-1,913
-69% -$65.3K ﹤0.01% 1407
2016
Q4 		$101K Sell
2,776
-27,915
-91% -$1.11M ﹤0.01% 1223
2016
Q3 		$1.41M Sell
30,691
-18,650
-38% -$973K 0.01% 535
2016
Q2 		$2.48M Sell
49,341
-1,222
-2% -$65.1K 0.01% 363
2016
Q1 		$2.71M Sell
50,563
-1,021
-2% -$59.9K 0.02% 359
2015
Q4 		$3.38M Buy
51,584
+19,201
+59% +$1.19M 0.02% 320
2015
Q3 		$1.83M Buy
32,383
+19
+0.1% +$1.23K 0.01% 439
2015
Q2 		$1.91M Buy
32,364
+30,048
+1,297% +$1.85M 0.01% 429
2015
Q1 		$144K Buy
2,316
+5
+0.2% +$291 ﹤0.01% 779
2014
Q4 		$133K Buy
2,311
+1,986
+611% +$111K ﹤0.01% 759
2014
Q3 		$17K Sell
325
-2,128
-87% -$113K ﹤0.01% 1033
2014
Q2 		$129K Buy
2,453
+1,198
+95% +$61.2K ﹤0.01% 735
2014
Q1 		$67K Sell
1,255
-200,449
-99% -$9.26M ﹤0.01% 805
2013
Q4 		$8.08M Sell
201,704
-2,512,446
-93% -$98.9M 0.06% 176
2013
Q3 		$103M Buy
2,714,150
+54,949
+2% +$2.14M 0.83% 53
2013
Q2 		$104M Buy
+2,659,201
New +$104M 0.93% 41

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Bessemer Group's TEVA Position: Q2 2026 in Review

Bessemer Group increased its Teva Pharmaceuticals (TEVA) stake by 28% in Q2 2026, buying an estimated $41M and bringing the position to 5,581,600 shares worth $189M. The position accounts for 0.26% of the portfolio, ranked #96.

Bessemer Group first reported a position in TEVA in Q2 2013 and has held it in 49 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Bessemer Group held 5,581,600 shares of Teva Pharmaceuticals worth $189M as of Q2 2026.
  • Bessemer Group bought 1,231,117 Teva Pharmaceuticals shares in Q2 2026, an estimated $41M.
  • Teva Pharmaceuticals made up 0.26% of Bessemer Group's portfolio in Q2 2026, its #96 holding.
  • Bessemer Group first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.